Regulatory FDA approves MSD’s Keytruda combinations for MIBC Pharmaceutical TechnologyThe FDA has approved two of MSD's anti-PD-1 therapies, Keytruda and Keytruda Qlex, along with Padcev, for adults with MIBC.OncologyRead full story pharminent July 13, 2026 (Last updated: July 13, 2026) Pharmaceutical Technology The FDA has approved two of MSD’s anti-PD-1 therapies, Keytruda and Keytruda Qlex, along with Padcev, for adults with MIBC. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Roche Scraps Two Ionis-Partnered Huntington’s Studies After Tominersen FailureNext: “Hub-and-spoke” drug manufacturing set to benefit from new FDA rule Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
